Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

Otsuka Pharmaceutical's sibeprenlimab showed a 51% reduction in proteinuria in a late-stage study for IgA nephropathy, leading to a sell-off of Vera Therapeutics' shares, though some analysts caution against overinterpreting the data; Arvinas and Pfizer filed for U.S. approval of vepdegestrant for breast cancer with a specific mutation, based on modest Phase 3 data; Regenxbio shares fell despite positive early-stage data on its Duchenne muscular dystrophy gene therapy due to concerns about data strength and plateauing effects; Vigil Neuroscience's mid-stage trial for ALSP failed, leading to discontinuation of a long-term extension study; and Sagimet Biosciences' shares rose following positive Phase 3 results in China for acne treatment denifanstat by partner Ascletis Bioscience, potentially impacting its use in treating metabolic dysfunction-associated steatohepatitis.

Analysis

The biopharmaceutical sector witnessed varied clinical and regulatory developments impacting investor sentiment across several firms. Vera Therapeutics experienced a significant market capitalization decline, losing nearly a third of its value, following Otsuka Pharmaceutical's presentation of late-stage data for its rival IgA nephropathy drug, sibeprenlimab, which demonstrated a 51% reduction in proteinuria. This compared to the 42% reduction shown by Vera's therapy at a similar juncture, prompting a sell-off despite some analysts, like Jefferies’ Farzin Haque, cautioning that the datasets are not definitively different for commercial uptake; Otsuka's drug has a PDUFA date of November 28, while Vera intends to file for accelerated approval in Q4. Conversely, Sagimet Biosciences' shares appreciated by nearly 40% after its partner, Ascletis Bioscience, reported positive Phase 3 results for denifanstat in treating moderate-to-severe acne in China, with Leerink Partners noting potential positive implications for the drug's development in metabolic dysfunction-associated steatohepatitis (MASH) and Sagimet standing to gain up to $122 million in milestones plus royalties. Arvinas, with partner Pfizer, submitted a U.S. approval application for vepdegestrant in ER+/HER2- breast cancer with an ESR1 mutation, based on Phase 3 data showing a modest improvement in tumor control over standard therapy, a benefit not observed across the entire study population. Regenxbio's shares declined by double digits despite releasing early-stage data for its Duchenne muscular dystrophy gene therapy indicating potential muscle function benefits compared to historical controls; Jefferies analyst Maury Raycroft cited concerns over missing information, apparent plateauing of treatment effects, and the data's sufficiency for an accelerated approval pathway, with pivotal data expected next year. Lastly, Vigil Neuroscience reported the failure of its mid-stage trial for VGL101 in ALSP, as the drug did not achieve beneficial effects on efficacy or biological markers, leading to the discontinuation of a related long-term study; rights for VGL101 will revert to Amgen, while Sanofi's acquisition of Vigil for a different asset continues.

Key Decisions for Investors

• Investors in Vera Therapeutics should closely monitor the competitive landscape, particularly Otsuka's upcoming PDUFA date and the specifics of Vera's Q4 accelerated approval filing, weighing the perceived efficacy differences against analyst commentary on commercial viability.
• For Arvinas, the modest clinical benefit of vepdegestrant warrants careful consideration of its market potential within the niche ESR1-mutated breast cancer segment and the regulatory risk associated with the current data package.
• Regenxbio investors should anticipate heightened volatility leading up to the pivotal data release next year, carefully assessing the risk-reward profile given current concerns about data robustness and the therapy's long-term efficacy trajectory.
• Following the VGL101 trial failure, Vigil Neuroscience investors should primarily focus on the value proposition of the Sanofi acquisition, which is centered on a different asset, and acknowledge the write-down of VGL101.
• Sagimet Biosciences' investors should assess the read-through potential of the positive Chinese acne data for denifanstat's MASH indication and factor in prospective milestone payments and royalties from the Ascletis partnership into their valuation.